M120风险评分改进对儿童发展为临床1型糖尿病高风险的识别,并报告对预防性免疫治疗的短期应答
研究在TrialNet多个胰岛自身抗体阳性参与者及加入teplizumab预防试验者中评估M120风险评分,结果显示M120较口服葡萄糖耐量试验多识别26%的高进展风险儿童;在teplizumab试验数据中,M120在teplizumab后改善(P=0.0362)、安慰剂后恶化(P=0.0489),6个月后显示显著治疗效果(P<0.001)。
要点
- M120风险评分较口服葡萄糖耐量试验多识别26%的高进展风险儿童。
- teplizumab后M120改善(P=0.0362),安慰剂后恶化(P=0.0489)。
- 6个月时M120显示显著治疗效果(P<0.001)。
核心结论
- M120改善风险分层并识别免疫治疗的早期效果,可用于提高预防试验效率并指导临床治疗决策。
研究设计与样本
- 在具有多个胰岛自身抗体的TrialNet参与者及加入teplizumab预防试验者中测定M120风险评分。
主要发现
- 与口服葡萄糖耐量试验相比,M120识别出多26%的进展高风险儿童。
- 在teplizumab试验数据中,M120在teplizumab后改善(P=0.0362),在安慰剂后恶化(P=0.0489)。
- 6个月后显示显著治疗效果(P<0.001)。
关键数值与推荐
- M120基于年龄、性别、BMI、IA-2抗体状态、HbA1c、血糖及口服葡萄糖后120分钟C肽。
临床怎么用
- M120可应用于提高预防试验效率并指导临床治疗决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approval of teplizumab as disease-modifying therapy for type 1 diabetes heralds a new therapeutic era. To facilitate prevention trials, we determined if the M120 risk score could enrich for type 1 diabetes risk and define early treatment effects. RESEARCH DESIGN AND METHODS: M120, based on age, sex, BMI, IA-2 antibody status, HbA1c, blood glucose, and C-peptide 120 min after oral glucose, was determined in TrialNet participants with multiple islet autoantibodies and those who joined the teplizumab prevention trial. RESULTS: Compared with the oral glucose tolerance test, M120 identified 26% more children at high risk of progression. When applied to data from the teplizumab trial, M120 improved after teplizumab (P = 0.0362) and deteriorated after placebo (P = 0.0489) to reveal a significant treatment effect after 6 months (P < 0.001). CONCLUSIONS: M120 improves risk stratification and identifies early effects of immunotherapy. It could be applied to increase prevention trial efficiency and guide treatment decisions in the clinic.
引用
- Le MV, Harrison LC, Spelman T, et al. M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy. Diabetes Care. 2025. PMID: 40208750. doi:10.2337/dc24-2794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。